- Lobbying
- Lobbying by Amneal Pharmaceutical
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Alexander Angelson | Special Assistant to the President, White House Legislative Affairs |
Olivia Imhoff | Deputy Associate Director, Executive Office of the President |
Andrea Riccio | Deputy Director Democratic Policy and Communications Committee, House of Representatives |
Sarah Helton | Intern, House of Representatives; Intern, Senate |
Bridget Visconti | Confidential Assistant to the USTR and Chief of Staff, Office of the United States Representative, Executive Office of the President; Executive Office Coordinator- Council of Economic Advisers, Executive Office of the President |
Nikhil Dhingra | Intern, House of Representatives |
Erik Berdy | Special Assistant to the Chairman of the Joint Chiefs of Staff for Legislative Affairs; Legislative Assistant to the Chief of Staff of the Army; Deputy Military Legislative Assistant, Senate |
Lewis Polay | Intern, House of Representatives |
Brett Ewer | Intern, Senate |
Denise Bode | n/a |
Lucia Alonzo | n/a |
Patrick Firth | n/a |
Emily Green | n/a |
Jenette Morell | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Health & Human Services - Dept of (HHS)
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
White House Office
U.S. Senate
Health & Human Services - Dept of (HHS)
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
White House Office
U.S. Senate
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
White House Office
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Amendment
Lobbying Issues
Agencies Lobbied
Type of Issue
Amendment
Lobbying Issues
Agencies Lobbied
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q1 Report
Registration
Issue(s) they said they’d lobby about: issues relating to manufacturing of pharmaceuticals.
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate